Literature DB >> 15780548

Knowledge of and interest in hepatitis C treatment at a methadone clinic.

Alexander Y Walley1, Mary C White, Margot B Kushel, Yong S Song, Jacqueline P Tulsky.   

Abstract

This study describes knowledge about hepatitis C virus (HCV) infection and interest in treatment among 110 opiate dependent patients from an opiate dependence treatment program in San Francisco. None had been treated for HCV and only 30% had been evaluated for HCV treatment. While only 34% knew about HCV treatment, 54% of the sample became "definitely interested" in HCV treatment after hearing the risks and benefits. Men were approximately five times more likely than women to know of some HCV treatment. Whites were seven times and Latinos were about six times more likely than African-Americans to know about HCV treatment. Our findings suggest that methadone programs can play an important role in increasing access to HCV treatment through educating patients about treatment options.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780548     DOI: 10.1016/j.jsat.2004.12.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  33 in total

1.  Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals.

Authors:  Kapil Gupta; Denise Romney; Muriel Briggs; Karen Benker
Journal:  J Community Health       Date:  2007-08

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

3.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

4.  Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada.

Authors:  Samantha Young; Evan Wood; M-J Milloy; Kora DeBeck; Sabina Dobrer; Ekaterina Nosova; Thomas Kerr; Kanna Hayashi PhD
Journal:  Subst Abus       Date:  2018-10-02       Impact factor: 3.716

5.  Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.

Authors:  Christine U Oramasionwu; Angela Dm Kashuba; Sonia Napravnik; David A Wohl; Lu Mao; Adaora A Adimora
Journal:  World J Hepatol       Date:  2016-03-08

6.  An interrupted time series evaluation of a hepatitis C intervention for persons with HIV.

Authors:  Rae Jean Proeschold-Bell; Bettina Hoeppner; Baishakhi Taylor; Sarah Cohen; Rachel Blouin; Beth Stringfield; Andrew J Muir
Journal:  AIDS Behav       Date:  2011-11

7.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

8.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02

9.  Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis.

Authors:  Sandra E Larios; Carmen L Masson; Michael S Shopshire; Jennifer Hettema; Ashly E Jordan; Courtney McKnight; Christopher Young; Mandana Khalili; Randy M Seewald; Albert Min; Nicholas Hengl; James L Sorensen; Don C Des Jarlais; David C Perlman
Journal:  J Subst Abuse Treat       Date:  2013-11-11

10.  Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

Authors:  J Grebely; K Petoumenos; G V Matthews; P Haber; P Marks; A R Lloyd; J M Kaldor; G J Dore; M Hellard
Journal:  Drug Alcohol Depend       Date:  2010-03-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.